Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsSUBCUTANEOUSGeneric

RASUVO

METHOTREXATE

Standard Dose
27.5MG/0.55ML (27.5MG/0.55ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview RASUVO is listed in Drugs@FDA under application 205776 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient METHOTREXATE Form and strength SOLUTION;SUBCUTANEOUS - 27.5MG/0.55ML (27.5MG/0.55ML) Sponsor MEDEXUS Submission history Latest submission status date: 2020-03-11 00:00:00.

Structured Monograph

Clinical summary

Approval overview RASUVO is listed in Drugs@FDA under application 205776 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient METHOTREXATE Form and strength SOLUTION;SUBCUTANEOUS - 27.5MG/0.55ML (27.5MG/0.55ML) Sponsor MEDEXUS Submission history Latest submission status date: 2020-03-11 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.